A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 96.67
GOOG 738.42
MSFT 56.76
FB 121.22
BAC 14.53

Recently Added

TSRO 90.05
ADPT 47.40
VNQ 91.16
VLUE 64.66
VIG 85.60

Gaining Speed

ADPT 47.40
TSRO 90.05
BSTG 1.09
AMC 29.94
WNC 13.05

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More

Get Alerted When News Hits On This Stock - FREE!